Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice

Roxanne Weiss, Elizabeth Fernandez, Yuhong Liu, Randy Strong, Adam B. Salmon

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The use of rapamycin to extend lifespan and delay age-related disease in mice is well-established despite its potential to impair glucose metabolism which is driven partially due to increased hepatic gluconeogenesis. We tested whether a combination therapeutic approach using rapamycin and metformin could diminish some of the known metabolic defects caused by rapamycin treatment in mice. In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment. In female mice, this defect was alleviated over time by simultaneous treatment with metformin, also by diet, such that females treated with both drugs where indistinguishable from control mice during glucose tolerance tests. While rapamycinmediated glucose intolerance was unaffected by metformin in males, we found metformin prevented rapamycin-mediated reduction in insulin and leptin concentrations following 9 months of co-treatment. Recently, the Interventions Testing Program showed that mice treated with metformin and rapamycin live at least as long as those treated with rapamycin alone. Together, our data provide compelling evidence that the pro-longevity effects of rapamycin can be uncoupled from its detrimental effects on metabolism through combined therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)386-401
Number of pages16
JournalAging
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2018

Keywords

  • AMPK
  • Adiponectin
  • Gluconeogenesis
  • Insulin
  • Interventions
  • Leptin
  • MTOR

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Fingerprint

Dive into the research topics of 'Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice'. Together they form a unique fingerprint.

Cite this